Extra Space Storage, Inc. vs Novartis AG — how do they compare? Extra Space Storage, Inc. trades at $146.41 (market cap $30.98B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 9.6× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| EXR | NVS | |
|---|---|---|
Market Cap | $30.98B | $298.18B |
Sector | Real Estate | Health |
52-Week High | $152.85 | $168.62 |
52-Week Low | $126.67 | $119.31 |
Enterprise Value | $44.70B | $339.50B |
Dividend Yield | 4.42% | 3.02% |
Signals from Pluang's Aura AI — not financial advice
EXR trades at $149.54, near its 52-week high, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q2 2026 core FFO of $2.15 per share, exceeding estimates, and raised full-year guidance. Revenue growth remains steady, with a net income margin of 27.79% in 2025, though valuation ratios like P/E of 33.01 suggest a premium pricing.
Outlook is positive with analyst consensus price target of $157.25, but risks include high debt levels and competitive pressures in the self-storage sector. The stock offers a dividend yield supported by solid cash flows, making it attractive for income-focused investors amid cautious market sentiment.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →